Finding Common Ground: Considerations for Making Treatment Decisions in R/R Follicular Lymphoma
Read More
Durvalumab Plus Chemo May be Promising Neoadjuvant Option in UTUC
Dr Patel on the Potential for Adjuvant Immunotherapy in CSCC
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
FDA Grants Priority Review to Perioperative Pembrolizumab in Resectable HNSCC
MD Anderson Receives Nearly $23 Million in CPRIT Funding for Cancer Research, Faculty Recruitment
Identifying and Addressing the Overlooked Need of Patient Sexual Health